ACET Adicet Bio
- 1.680
- -0.130-7.18%
- 1.721
- +0.041+2.46%
Adicet Bio News
Express News | Wedbush Reiterates Outperform on Adicet Bio, Maintains $5 Price Target
Express News | Adicet Today Presented Abstract Featuring Preclinical Data Highlighting ADI-270 At ASGCT27th Annual Meeting
Express News | Adicet Bio Inc - Preclinical Findings Showed Robust Anti-Tumor Activity of Adi-270 in Multiple Cd70-Positive Solid and Hematological Cancer Models
Express News | Adicet Bio Inc - on Track to File an Investigational New Drug (Ind) Application for Adi-270 in 2Q 2024
Express News | Adicet Bio Inc - Adi-270 Demonstrated Enhanced Functional Potency and Resilience in Tumor Microenvironment
Express News | Adicet Bio Highlights Preclinical Data Supporting Ind Readiness for Adi-270 in an Oral Presentation at the American Society of Gene and Cell Therapy (Asgct) 27TH Annual Meeting
Adicet Bio to Participate in 2024 Canaccord Genuity Horizons in Oncology Virtual Conference
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President
Adicet Bio Is Maintained at Buy by HC Wainwright & Co.
Adicet Bio Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Adicet Bio, Maintains $10 Price Target
Analysts Offer Insights on Healthcare Companies: Genelux Corp. (GNLX), Adicet Bio (ACET) and Entera Bio (ENTX)
Adicet Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmun
Adicet Bio To Present At H.C. Wainwright Cell Therapy Virtual Conference; Webcast 10:30 AM ET
Express News | Adicet Bio May Offer And Sell Shares Of Common Stock Having An Aggregate Offering Price Of Up To $100M From Time To Time
BGFV, STI and HNST Are Among After Hour Movers
Adicet Bio (ACET) Receives a New Rating From Truist Financial
Are Investors Undervaluing Adicet Bio, Inc. (NASDAQ:ACET) By 41%?
Adicet Bio Inc (ACET) Reports Q4 and Full Year 2023 Financial Results
Adicet Bio: A Strong Buy on Robust Financials and Promising Clinical Trials
Buy Rating Affirmed for Adicet Bio Amid Promising CAR T-Cell Therapies and Strong Financial Footing
Adicet Bio Price Target Maintained With a $5.00/Share by Wedbush
Adicet Bio Price Target Maintained With a $5.00/Share by Wedbush
Analysis
Price Target
No Data
